Clinical trials: Rectum Cancer
Colorectal Cancer
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
PURPOSE: Phase II trial to study the effectiveness of combining capecitabine and irinotecan in treating patients who have locally advanced, recurrent, or metastatic colorectal cancer.
- Trial name
- NCT00022698
- Testing
- Capecitabine, Irinotecan
- Where
- 17 sites in United States
- Volunteers
- 67 people
- Sponsor
- Hoffmann-La Roche
Colon Cancer, Rectal Cancer
Survivor Choices for Eating and Drinking - Colorectal Cancer
Epidemiologic data suggest that a Western dietary pattern after diagnosis of colorectal cancer increases risk of disease recurrence and death.
- Conditions
- Colon Cancer, Rectal Cancer, ColoRectal Cancer
- Trial name
- SUCCEED (NCT02965521)
- Testing
- Website and text messages
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Rectal Cancer, Colorectal Cancer
The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial
The purpose of this study is to determine the feasibility of a prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant chemotherapy and/or radiation, followed by surgical resection.
- Conditions
- Rectal Cancer, Colorectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- NCT06565052
- Testing
- Prehabilitation Program
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer
Lymphatic Mapping, Sentinel Lymph Node Analysis, and Blood Tests in Detecting and Predicting Early Micrometastases in Patients With Colorectal Cancer
RATIONALE: Diagnostic procedures, such as lymph node mapping during surgery and sentinel lymph node biopsy, may help doctors find micrometastases and predict cancer recurrence.
- Trial name
- NCT00625625
- Testing
- isosulfan blue, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Volunteers
- 225 people
- Sponsor
- Saint John's Cancer Institute
Rectal Adenocarcinoma, Rectal Cancer
ctDNA-Informed Management of Early-Stage Rectal Cancer
This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay.
- Conditions
- Rectal Adenocarcinoma, Rectal Cancer, Early-stage Rectal Cancer, Locally Advanced Rectal Adenocarcinoma
- Trial name
- ULTIMATE (NCT07209215)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of California, Davis
Low Anterior Resection Syndrome, Rectal Cancer
Transanal Irrigation for the Management of LARS
This study aims to evaluate the impact of Transanal irrigation (TAI) on the quality of life and low anterior resection symptoms (LARS) in Canadian rectal cancer survivors living with minor to major LARS.
- Trial name
- TAI-LARS (NCT05007015)
- Testing
- Transanal Irrigation
- Where
- 8 sites in Canada
- Volunteers
- 66 people
- Sponsor
- Jewish General Hospital
Gastric Cancer, Hepatocellular Carcinoma
Personalized DC Vaccine for Postoperative Cancer
The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and…
- Conditions
- Gastric Cancer, Hepatocellular Carcinoma, Non-Small-Cell Lung Cancer, Colon Rectal Cancer
- Trial name
- NCT04147078
- Testing
- DC vaccine subcutaneous administration
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan University
Rectal Cancer
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together…
- Trial name
- NEO-RT (NCT06205485)
- Testing
- Leucovorin, Oxaliplatin, Fluoruracil
- Where
- 113 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer, Colo-rectal Cancer
Feasibility Study of a Molecular Karyotype Using a Very High-throughput Sequencing Approach, the "Massive Parallel Sequencing" on Circulating Tumor DNA
There are several types of circulating DNA: DNA from patient's existing cells, foetal DNA in the case of pregnant woman, and tumoral DNA in the case of patients with cancer.
- Trial name
- NCT04104633
- Testing
- Blood samples
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Centre Hospitalier Henri Duffaut - Avignon
Rectal Cancer
Comparing Preoperative Short-course Radiotherapy With or Without Local Boost for Rectal Cancer
A randomized trial comparing weather preoperative short-course radiotherapy with local boost is better than conventional preoperative short-course radiotherapy for local advanced rectal cancer.
- Trial name
- NCT02498353
- Testing
- preoperative short-course radiotherapy with local boost, preoperative short-course radiotherapy without local boost, TME surgery
- Volunteers
- 100 people
- Sponsor
- Zhongnan Hospital
Rectal Cancer
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
The purpose of this Phase II study will be to investigate the antiangiogenic agent, aflibercept, in combination with chemoradiation as preoperative treatment for patients with stage II/III rectal cancer, followed by 4 months of…
- Trial name
- NCT01749956
- Testing
- Radiation, Aflibercept, Surgery
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- SCRI Development Innovations, LLC
Rectal Tumour
Transanal Endoscopic Microsurgery (TEM) After Radiochemotherapy for Rectal Cancer
In the Netherlands approximately 2300 new patients are diagnosed with rectal cancer each year. Standard treatment for patients with a T2 or T3 rectal cancer consists of preoperative short course of radiotherapy followed by…
- Trial name
- CARTS (NCT01273051)
- Testing
- Capecitabine, radiotherapy, TME resection
- Where
- 13 sites in Netherlands
- Volunteers
- 55 people
- Sponsor
- Radboud University Medical Center
Colo-rectal Cancer
Computed Tomography Perfusion Colorectal Cancer With Tumor Grade
Colorectal cancer is the third most commonly diagnosed cancer in the world. The 5-years survival rate depends on the tumor stage and grade at patient presentation.
- Trial name
- NCT03448302
- Testing
- Computed tomography perfusion
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Rectal Cancer
A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis
The purpose of this study is the increase of resection rate of primary cancer in rectal after short course radiotherapy without interrupt chemotherapy schedule during the period of chemotherapy.
- Trial name
- NCT01269229
- Testing
- folfox, short course Radiotherapy
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Yonsei University
Cancer of Colon, Cancer of Rectum
Clinical Trial Comparing Standard Care Versus Prehabilitation in Patients Undergoing Cancer Surgery
To determine whether exercise and nutrition prehabilitation improves patient outcomes after cancer surgery
- Conditions
- Cancer of Colon, Cancer of Rectum, Liver Metastases
- Trial name
- SPECS (NCT04880772)
- Testing
- Prehabilitation
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- East Lancashire Hospitals NHS Trust
Cancer
Care Pathways for Colorectal Cancer Surgery
EVALUATE THE CARE PROCESS AND THE QUALITY OF CARE FOR ADULT CANCER PATIENTS WHO ARE ADMITTED FOR COLORECTAL SURGERY
- Trial name
- CP4GICAN (NCT02965794)
- Testing
- Care pathways for colorectal cancer
- Where
- Belgium
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- European Pathway Association
Locally Advanced Rectal Cancer
Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study
The use of preoperative chemoradiation and adjuvant chemotherapy with 5-FU based chemotherapy reduced local recurrence rate to less than 10%, but has only had limited effect on overall survival due to the constantly high (more…
- Trial name
- CRAB (NCT00842686)
- Testing
- bevacizumab, capecitabine
- Where
- Slovenia
- Volunteers
- 60 people
- Sponsor
- Institute of Oncology Ljubljana
Neoplasms, Adenocarcinoma
Beyond TME Origins
All patients with recurrent colorectal cancer in the pelvis are eligible. The original primary tumour staging scans and resected surgical specimen needs to be available.
- Conditions
- Neoplasms, Adenocarcinoma, Carcinoma
- Trial name
- NCT02292641
- Testing
- New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery
- Where
- 4 sites in Norway, United Kingdom
- Volunteers
- 383 people
- Sponsor
- Imperial College London
Non-Small Cell Lung Cancer, Renal Cell Cancer
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers.
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer
- Trial name
- NCT03454451
- Testing
- CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
- Where
- 27 sites in United States, Australia
- Volunteers
- 117 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Locally Advanced Rectal Cancer (LARC)
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor…
- Trial name
- FORTRESS (NCT06459869)
- Testing
- NG-350A IV administration, Capecitabine oral administration, Radiotherapy
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Akamis Bio